Paul Sun, President and CEO of the Company commented: ...
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback